Medical Device Investing

Medical device investing runs on a different clock and a different risk profile than therapeutics. The regulatory path — a 510(k) clearance against a predicate device, or a longer de novo or PMA route for something genuinely novel — is often shorter than a drug's clinical pathway, but engineering, manufacturing, and reimbursement questions arrive earlier and carry real weight in whether the company is investable.

A device can perform well on the bench and still be a difficult investment if three questions have not been answered: does the regulatory and predicate strategy hold up to scrutiny, can the device be manufactured at the tolerances and cost the business model requires, and will a clinician, health system, or payer actually adopt and pay for it once it is cleared. The first two are engineering and regulatory questions; the third is a commercial one, and it is the one many technically strong device companies underrate.

Investors newer to the category often focus heavily on the clinical data and underweight manufacturing and reimbursement — exactly the two areas that tend to surface late and derail otherwise promising companies.